ClearPoint Neuro (NASDAQ:CLPT) Issues Earnings Results

ClearPoint Neuro (NASDAQ:CLPT) posted its earnings results on Tuesday. The company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.07), Zacks reports. ClearPoint Neuro had a negative return on equity of 62.10% and a negative net margin of 59.64%. The company had revenue of $8.49 million for the quarter, compared to the consensus estimate of $8.21 million. ClearPoint Neuro updated its FY 2025 guidance to EPS.

ClearPoint Neuro Price Performance

ClearPoint Neuro stock opened at $12.43 on Thursday. The firm has a market cap of $347.79 million, a P/E ratio of -18.01 and a beta of 1.03. The stock’s 50 day moving average is $12.84 and its 200 day moving average is $14.22. ClearPoint Neuro has a one year low of $5.11 and a one year high of $19.22.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Lake Street Capital upped their target price on ClearPoint Neuro from $17.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday, January 21st. B. Riley raised their price objective on shares of ClearPoint Neuro from $15.00 to $20.00 and gave the company a “buy” rating in a report on Tuesday, January 28th. Finally, Stifel Nicolaus boosted their target price on shares of ClearPoint Neuro from $19.00 to $25.00 and gave the stock a “buy” rating in a report on Tuesday, April 1st.

About ClearPoint Neuro

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.